



Универзитет у Београду

Фармацеутски факултет

## OKRUGLI STO

### DNEVNI RED

1. Prikaz određenih mogućnosti za projektna finansiranja i sprovođenje međunarodne saradnje - sagledavanje potrebe za dodatnim obukama i boljim informisanjem - koncept aplikacija za projekte: interno organizovanje ili *outsourcing*, šta je optimalno i moguće? (razmena informacija i iskustava)
2. Osvrt na predlog o potrebi racionalnog organizovanja istraživačkih kapaciteta na FF-u: da li potreba postoji, kako vidimo i da li je potrebno efektivnije i racionalnije korišćenje, razmatranje nabavki nove i servisiranje postojeće opreme za naučno-istraživački rad? (Prilog: kratak osvrt na trenutno stanje i mogućnosti reorganizovanja).
3. Formiranje repozitorijuma - *Open science* koncept: implikacije za prospektivne aplikacije na projekte koje (ko)finansira EC.
4. Nacrt Zakona o nauci i straživanjima: objedinjeni komentari i reakcije – da ili ne?

# Nacionalno finansiranje?

Наставници и сарадници Факултета су у току 2017. године објавили 2 поглавља у истакнутим монографијама међународног значаја (M13) и 12 поглавља у монографији међународног значаја (категорија M14), као и једно уређивање монографије међународног значаја (M18).

Публиковано је укупно **231** рад у међународним и националним часописима: од тога 76 у врхунским међународним часописима – **12 у категорији M21a (међународни часопис изузетних вредности – за школску 2017/2018. - 14 награда додељено 19.10.2018)** и **67 у категорији M21 (врхунски међународни часопис)**; **51 у истакнутим међународним часописима – категорија M22**; **68 у међународним часописима – категорија M23**.

Публикована је једна научна критика и полемика у међународном часопису (M26), уређиван је један међународни часопис (резултат категорије M28). Публикована је једна монографија националног значаја (категорија M42), 5 радова у часописима националног значаја изузетних вредности (категорија M51), 8 радова у истакнутим националним часописима (категорија M52) и 17 у часописима националног значаја (категорија M53). Реализовано је једно ново техничко решење (производ) примењено на националном нивоу (M82), једно битно побољшано техничко решење на међународном нивоу (M83) и 2 нова техничка решења (M85).

## Bilateralni projekti

- U poslednjih **5 godina 15 bilateralnih projekata na FF** – ko-finansiranih od strane MPNTR-a, sa Nemačkom, Italijom, Austrijom, Kinom, Slovenijom, Hrvatskom, Crnom Gorom...
- Trenutno je aktuelno 6 bilateralnih projekata (Austrija, Kina, Nemačka, Slovenija, Crna Gora)

# Bilateralni projekti – osnovne informacije

- Konkursi i aktuelne informacije: <http://www.mpn.gov.rs/medjunarodna-naucna-saradnja/>
- Bilateralna saradnja između Srbije i:
  - Austrije
  - Belorusije
  - Kine
  - Mađarske
  - Italije
  - Nemačke
  - Portugalije
  - Slovenije
  - Slovačke
  - Francuske
  - Hrvatske
  - Crne Gore

## Bilateralni projekti – osnovne informacije?

- **Refundacija troškova puta i boravka istraživača u partnerskoj instituciji** (institucija koja šalje istraživača – refundacija troškova puta; institucija koja prima istraživača – refundacija troškova boravka)
- **Troškove istraživanja snosi svaka od dve institucije.** Ovi troškovi se ne refundiraju iz sredstava bilateralnog projekta
- Trajanje projekta: 2 ili 3 godine
- **Pravilnik koji uređuje ove aspekte?** – postoje primeri na UB/institutima.

## Bilateralni projekti – benefiti?

- Upoznavanje istraživača sa radom u laboratorijama u inostranstvu.
- Mogućnost da se deo doktorske disertacije (za doktorante) ili kompleksnog istraživanja uradi u inostranstvu.
- Ostvarivanje novih/jaćanje postojećih kontakata sa istraživačima iz inostranstva.
- Postavljanje temelja za druge vidove saradnje (npr. konkurisanje za HORIZON 2020/Europe projekte).



COST is supported by the Framework  
Programme Horizon 2020



# COST akcije

- **European Co-operation in the Field of Scientific and Technical Research – COST**
- **Evropski program za saradnju u domenu naučnih i tehnoloških istraživanja**
- **Na FF-u – istraživači učestvuju u 15 COST akcija koje su u toku.**



## Šta su COST akcije?



- ✓ Programi iz COST domena predstavljaju međuvladin okvir za saradnju na polju nauke i tehnologije, koji omogućuje koordinaciju istraživanja na evropskom nivou.
- ✓ COST program promoviše interdisciplinarna istraživanja i međunarodnu saradnju, uz povezivanje akademije, industrije, javnog i privatnog sektora u jednu otvorenu mrežu.
- ✓ COST akcija predstavlja internacionalni naučno-istraživački projekat koji se bavi temom od zajedničkog interesa, a **za istraživanja koristi nacionalne fondove.**
- ✓ Svaka COST akcija mora imati barem 5 zemalja koje podržavaju realizaciju (predlagač i još 4 zemlje)\*
- ✓ Trajanje COST akcije je 4 godine.
- ✓ Aktivnosti COST akcije koordinira Upravni odbor (*Management committee – MC*).

**\*Trenutno je 38 zemalja COST članica:** Albanija, Austrija, Belgija, Bosna I Hercegovina, Bugarska, Hrvatska, Kipar, Češka, Danska, Estonija, Finska, Francuska, Nemačka, Grčka, Mađarska, Island, Irska, Italija, Letonija, Litvanija, Luksemburg, Malta, Moldavija, Crna Gora, Holandija, Norveška, Poljska, Portugalija, Rumunija, **Srbija**, Slovačka, Slovenija, Španija, Švedska, Švajcarska, Turška, Ujedinjeno Kraljevstvo Velike Britanije i Severne Irske, Makedonija.



## Kako se može učestvovati u COST akcijama?



- ✓ Dva puta godišnje raspisuje se Otvoreni poziv (*COST Open Call*) za prijavu predloga za COST akciju (*COST Action Proposal*)
- ✓ Podnose se predlozi za istraživanja koja bi doprinela naučnom, ekonomskom, tehnološkom i kulturološkom napretku u Evropi, a favorizuju se **multi- i interdisciplinarni predlozi**.
- ✓ Članica koja predlaže COST akciju mora imati podršku barem još 4 zemlje.
- ✓ Pristupanje COST akciji se ostvaruje Memorandumom o (spo)razumevanju (*Memorandum of Understanding – MoU*).
- ✓ Republika Srbija može biti predlagač neke COST akcije, kao i član COST akcije koju je predložila druga zemlja.
- ✓ Predlog COST akcije i njena evaluacija moraju biti u skladu sa SESA vodičem  
(*Submission, Evaluation, Selection and Approval Guideline*)

MoU sadrži opis projekta, definiše ciljeve, vremenske odrednice, radne pakete i radne grupe za sprovedene aktivnosti na COST akciji.

Princip  
OTVOREN  
-OG  
PRISTUPA

- ✓ Postojeće COST akcije mogu se podeliti na one koje su započete, u toku i završene akcije.
- ✓ Postoji mogućnost naknadnog priključivanja akciji koja je u toku, pod uslovom da nije u završnoj fazi realizacije (3. i 4. godina).



# Kako se realizuju i finansiraju COST akcije?



✓ Istraživanja u okviru COST akcije treba da se oslone na postojeći projekat (nacionalni, evropski) preko kojeg se obezbeđuje finansiranje ove aktivnosti.

COST  
akcija ne  
finansira  
istraživanje.

✓ U okviru COST akcije, u toku njene realizacije, moguće je organizovati letnje škole, seminare, sastanke, konferencije, ili odlaske u kratke naučne posete.

To su aktivnosti koje finansira COST akcija.

COST akcija može finansirati određene aktivnosti koje doprinose komunikaciji među učesnicima akcije, diseminaciji znanja i rezultata...

✓ Za koordinaciju COST akcijom odgovoran je *Management Committee* (MC) – svaka zemlja članica Akcije ima pravo na 2 predstavnika u MC.

✓ Učešće u COST akciji može biti realizovano kroz radnu grupu koja sprovodi aktivnosti u skladu sa ciljevima projekta i/ili učešćem kroz aktivnosti COST akcije (škole, seminari...)



## Korisni linkovi

- ✓ Osnovne informacije o COST akciji i kontakt osobe u Srbiji

<http://www.mpn.gov.rs/cost/>

- ✓ COST Action internet prezentacija

<https://www.cost.eu/>

Detaljne i ažurne  
informacije, konkursi,  
vodiči...

# Horizon2020

(2014 – 2020)



# HorizonEurope

(2021 – 2028)

- Spreading Excellence and Widening Participation/actions
- Marie Skłodowska-Curie actions
- Innovative Medicines Initiative (IMI2 + IMI3)
- ERC Grants

PIC Number: 924988800, LEAR: prof. dr Svetlana Ibrić



European Commission  
Research & Innovation - Participant Portal  
Proposal Submission Forms

Proposal ID **821528-2**

Acronym **NeuroDeRisk**

Short name **UNIBEO**

**PIC**

924988800

**Legal name**

FARMACEUTSKI FAKULTET UNIVERZITETAU BEOGRADU

*Short name: UNIBEO*

*Address of the organisation*

Street VOJVODE STEPE 450

Town BELGRADE

Postcode 52600

Country Serbia

Webpage <http://www.pharmacy.bg.ac.rs/en/>



# NeuroDeRisk

---

*Improving the preclinical prediction of adverse effects  
of pharmaceuticals on the nervous system*

**Proposal Number:** 821528-2


**Topic:** IMI2-2017-13-10

---



# The calendar

Ready to start 1Q2019; finish 3Q2022







European Commission > Funding, Tenders > Funding opportunities > Funding programmes > Horizon 2020 >

Horizon 2020



What is  
Horizon 2020?

Find  
Your area

How to  
Get funding?

News, Events  
& Publications

Projects

The next  
Framework Programme

Sections navigation


Spreading Excellence and Widening Participation

### What are the core Widening actions?

Widening consists of three main actions, i.e.

**Teaming, Twinning** and **ERA Chairs**, for which specific eligibility conditions apply. This ensures a targeted approach towards Widening Member States and Associated Countries. The **Member States** currently eligible for Widening support are: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia and Slovenia.

**The Associated Countries** currently eligible for Widening support are (subject to valid association agreements of third countries with Horizon 2020): Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Former Yugoslav Republic of Macedonia, Georgia, Moldova, Montenegro, **Serbia**, Tunisia, Turkey and Ukraine.





European Commission > Funding, Tenders > Funding opportunities > Funding programmes > Horizon 2020 >

Horizon 2020



What is  
Horizon 2020?

Find  
Your area

How to  
Get funding?

News, Events  
& Publications

Projects

The next  
Framework Programme

Sections navigation

Spreading Excellence and Widening Participation

**Teaming** will invest in Europe's research and innovation potential through supporting the creation of new (or upgrading of existing) Centres of Excellence in low R&I performing Member States and Associated Countries on the basis of partnerships with internationally leading institutions.

**Twinning** aims to build on the huge potential of networking for excellence through knowledge transfer and, exchange of best practice between research institutions and leading partners.

**ERA Chairs** will bring outstanding researchers to universities and other research organisations, in those countries, that have high potential for research excellence to help them attract, maintain and increase high quality human resources and implement the structural changes necessary to achieve excellence on a sustainable basis.



*Više podataka u dokumentu:*

EN

Horizon 2020

Work Programme 2018-2020

*15. Spreading Excellence and Widening Participation*

**IMPORTANT NOTICE ON THIS WORK PROGRAMME**

This Work Programme covers 2018, 2019 and 2020. The parts of the Work Programme that relate to 2019 (topics, dates, budget) have, with this revised version, been updated. The changes relating to this revised part are explained on the Participant Portal. The parts that relate to 2020 are provided at this stage on an indicative basis. Such Work Programme parts will be decided during 2019.

*(European Commission Decision C(2018)4708 of 24 July 2018)*



## WIDESPREAD-03-2018: Twinning

**Specific Challenge:** The specific challenge is to enhance networking activities between the research institutions of the Widening countries and internationally-leading counterparts at EU level. Driven by the quest for excellence, research intensive institutions tend to collaborate increasingly in closed groups, producing a crowding-out effect for a large number of promising institutions. This is the challenge that a specific Twinning action will try to address.

**Scope:** Twinning aims at significantly strengthening a defined field of research in a university or research organisation from a Widening country by linking it with **at least two** internationally-leading research institutions from two different Member States or Associated Countries.

### Twinning will:

1. Enhance the scientific and technological capacity of the linked institutions with a principal focus on the university or research organisation from the Widening Country;
2. Help raise the research profile of the institution from the Widening country as well as the research profile of its staff.

 Search

- Such a strategy should include a comprehensive set of activities to be supported:
  - **short term staff exchanges;**
  - **expert visits and shortterm on-site or virtual training;**
  - **workshops;**
  - **conference attendance;**
  - **organisation of joint summer school type activities;**
  - **dissemination and outreach activities.**
  
- A dedicated focus towards promoting the involvement of **early stage researchers** (as per the MSCA definition<sup>13</sup>) in the coordinating institution from the Widening country is expected.
  
- In general, **costs** relating to **administration, networking, coordination, training, management, travel costs** are **acceptable** under a Twinning project.
  
- Therefore, for grants awarded under this topic and type of action the following cost categories will be **ineligible costs**:
  - **infrastructure costs;**
  - **equipment;**
  - **research costs (including consumables).**

 Search

Type of Action: **Coordination and support action**

- **Increased research excellence** of the coordinating institution in the particular field of research as a result of the twinning exercise.
- **Enhancing the reputation**, attractiveness and networking channels of the coordinating institution.
- **Improved capability to compete successfully for national, EU and internationally competitive research funding.**
- **Illustrate quantitatively and qualitatively the expected potential impact** of the twinning exercise within the coordinating institution (and possibly at regional/national level) based on indicators like expected future publications in peer reviewed journals, collaboration agreements with businesses, intellectual property, new innovative products or services.
- It should be explained how the leading scientific institutions in the partnership will contribute in terms of provision of access to new research avenues, creativity and the development of new approaches, as well as **acting as a source for increased mobility (inwards and outwards) of qualified scientists.**
- The benefits for the internationally leading scientific institutions and the way they would materialise through the partnership should be substantiated.



Search

European Commission > Funding, Tenders > Funding opportunities > Funding programmes > Horizon 2020 >

Horizon 2020



What is Horizon 2020?

Find Your area

How to Get funding?

News, Events & Publications

Projects

The next Framework Programme

Sections navigation

Spreading Excellence and Widening Participation

WIDESPREAD-03-2018

1. The applicant organisation (coordinator) where a defined field of research aims to be strengthened as a result of the Twinning action should be established in a Member State or Associated Country that is ranked below 70% of the EU27 average of the composite indicator on Research Excellence<sup>21</sup>.

The selected corrective threshold of 70% of the EU average has been chosen in line with the particular policy requirements of the measure, to ensure the greatest possible impact through targeting only the lowest performing Member States, and thereby maximising the real value of these actions.

The duration of a Twinning project can be up to 3 years.

2. Twinning proposals must involve a minimum of three participants:

a. The applicant organisation must satisfy the condition set out in point 1 above, and must be the coordinator of the proposal.

b. At least two internationally-leading research intensive counterparts that must be coming from two different Member States or Associated Countries other than that of the coordinating applicant.

3. The requested EU contribution shall not exceed a maximum of EUR 0.8 million for a period of up to 3 years.



European Commission > Funding, Tenders > Funding opportunities > Funding programmes > Horizon 2020 >

Horizon 2020



What is  
Horizon 2020?

Find  
Your area

How to  
Get funding?

News, Events  
& Publications

Projects

The next  
Framework Programme

Search

Sections navigation

Spreading Excellence and Widening Participation

*Horizon 2020 - Work Programme 2018-2020  
Spreading Excellence and Widening Participation*

## **CALLS and OTHER ACTIONS for 2020<sup>35</sup>**

### **Call - WIDESPREAD**

**H2020-WIDESPREAD-2018-2020-continued**

Indicative budget for 2020:

**EUR 119 million**

Topics

**WIDESPREAD-05-2020: Twinning**

**WIDESPREAD-06-2020: ERA Chairs**

# Marie Skłodowska-Curie Actions

Home Actions How to... News & Events Resources Contact



## MARIE SKŁODOWSKA-CURIE ACTIONS

### Osnovne vrste MSC akcija:

- Marie Skłodowska-Curie Innovative Training Networks*
- Marie Skłodowska-Curie Individual Fellowships*
- Marie Skłodowska-Curie Research and Innovation Staff Exchange*
- Marie Skłodowska-Curie Co-funding of regional, national and international programmes*
- European Researchers' Night*
- MSCA for researchers at risk*



# H2020-MSCA-ITN-2019: Innovative Training Networks

- Objective:

ITN  
rese  
idea  
• S  
ITN  
prog  
rese  
diffe

ISKUSTVA....(?)

**START PAGE**

MARIE SKŁODOWSKA-CURIE ACTIONS

**Innovative Training Networks (ITN)**  
**Call: H2020-MSCA-ITN-2016**

PART B  
"I-Skin"

Advancing *in-vivo*, *in-vitro* and *in-silico* approaches for **skin** research and industrial applications

stage  
nd  
  
  
  
  
dini:

3 ti  
➤  
➤  
➤

Deadlines

MSCA-ITN-2019 (MSCA-ITN-ETN)	400.00
MSCA-ITN-2019 (MSCA-ITN-EID)	35.00
MSCA-ITN-2019 (MSCA-ITN-EJD)	35.00
Overall indicative budget	470.00

15 Jan 2019

Consortium Member	Legal Entity Short Name	Academic (tick)	Non-academic (tick)	Awards Doctoral Degrees (tick)	Country	Dept./ Division / Laboratory	Scientist-in-Charge	Role of Partner Organisation
<b>Beneficiaries</b>								
1 University of Surrey	UoS	Y		Y	UK	Chemical Engineering	Prof G Lian	Coordinator, Research, Training, Secondment
2 University College London	UCL	Y		Y	UK	School of Pharmacy	Dr M Lane	Research, Training, Secondment
3. Univerzita Palackeho v Olomouci	UPOL	Y		Y	Czech Republic	Regional Centre of advanced technology and Material	Dr Karel Berka	Research, Training, Secondment
4 University of Belgrade	UoB	Y		Y	Serbia	Pharmaceutical Technology	Prof S Savic	Research, Training, Secondment
5 Freie Universitat Berlin	FUB	Y		Y	Germany	Institute of Pharmacy	Prof M Schafer-Korting	Research, Training, secondment
6 MyLife Technologies	MyLife		Y		Netherlands	SME	Mr P Vos	Research, Secondment
7 RiverD International	RiverD		Y		Netherlands	SME	Dr G Puppels	Research, Secondment
8 Unilever UK Central Resources	Unilever		Y		UK	Strategic Science Group	Dr P Pudney	Research, secondment
9 Across Barriers GmbH	ACB		Y		Germany	SME	Mr E Haltner	Research, Secondment
10 Eindhoven University of Technology	TUe	Y		Y	Netherlands	Mechanical Engineering	Prof R Luttge	Research, Training, Secondment
11 Erasmus University Medical Center Rotterdam	EMCR	Y		Y	Netherlands	Dermatology	Dr P Caspers	Research, Training, Secondment
<b>Partner Organizations</b>								
12 NPL Management Ltd	NPL		Y		UK	Analytical Science Division	Dr A M Harling	Training Secondment
13 DCP Hemigal	DCPH		Y		Serbia	SME	Dr N Cekic	Secondment

# H2020-MSCA-IF-2019: Individual Fellowships


- Objective:

To enhance the creative and innovative potential of **experienced researchers**, wishing to diversify their individual competence in terms of skill acquisition through advanced training, international and intersectoral mobility.

- Scope:

Support is foreseen for individual, trans-national fellowships awarded to the best or most promising researchers of any nationality, for employment in EU Member States or Horizon 2020 Associated Countries. It is based on an **application made jointly by the researcher and the beneficiary** in the academic or non-academic sectors.

Više podataka  
u dokumentu:



## Budžet za MSCA-IF projekte u 2019. godini:

Opening date(s), deadline(s), indicative budget(s):<sup>21</sup>

Topics (Type of Action)	Budgets (EUR million)	Deadlines
	2019	
	Opening: 11 Apr 2019	
MSCA-IF-2019 (MSCA-IF-EF-CAR)	236.49	11 Sep 2019
MSCA-IF-2019 (MSCA-IF-EF-RI)		
MSCA-IF-2019 (MSCA-IF-EF-ST)		
MSCA-IF-2019 (MSCA-IF-EF-SE)	8.00	
MSCA-IF-2019 (MSCA-IF-GF)	50.00	
Overall indicative budget	294.49	

# MSCA-RISE-2019: Research and Innovation Staff Exchange

- Objective:

The RISE scheme **promotes international and cross-sector collaboration through exchanging research and innovation staff, and sharing knowledge and ideas from research to market** (and vice-versa). The scheme fosters a shared culture of research and innovation that welcomes and rewards creativity and entrepreneurship and helps to **turn creative ideas into innovative products, services or processes**.

- Scope:


RISE involves **organisations from the academic and non-academic sectors (in particular SMEs)**, based in Europe (EU Member States and Horizon 2020 Associated Countries) and outside Europe (third countries).



7. marta 2017. EU objavila da je kroz MSCA projekte podržala rad 100 000 istraživača.

## Budžet za MSCA-RISE projekte u 2019. godini:

Topics (Type of Action)	Budgets (EUR million)	Deadlines
	2019	
	Opening: 04 Dec 2018	
MSCA-RISE-2019 (MSCA-RISE)	80.00	02 Apr 2019
Overall indicative budget	80.00	



10 YEARS OF  
BREAKTHROUGHS  
A HEALTHIER  
FUTURE

We are an EU public-private partnership  
funding health research and innovation

**€5.3bn**  
BUDGET

**107**  
PROJECTS

**2220**  
PARTICIPANTS

**>7 000**  
PROJECT OUTPUTS

**>3 800**  
PUBLICATIONS

## IMI 1: 2008-2013

Budžet od 2 milijarde €  
59 projekata

## IMI 2: 2014-2020


Budžet od 3,3 milijarde €



European Federation of Pharmaceutical  
Industries and Associations

- Uključeno preko 9000 istraživača.

- EUFEPS se sastaje sa zvaničnicima EU u Lisabonu – dogovor o **IMI 3**.



# Open calls

## IMI2

- [IMI2 - Call 16](#)

Launched on 18 July 2018

Topics on antimicrobial resistance

- [IMI2 - Call 15](#)

Launched on 18 July 2018

Topics on integrated research platforms, digital clinical trials, immune-mediated diseases, medicines safety, brain disorders, blockchain, antimicrobial resistance

- [IMI2 - Call 14](#)

Launched on 15 March 2018

Topics on immune diseases, imaging, machine learning, decentralised clinical trials

- [IMI2 - Call 13](#)

Launched on 30 November 2017

Topics on heart disease, inflammatory skin disease, antimicrobial resistance, neurodegenerative diseases, stem cells, mobility, cancer, toxicology, medicines safety, repurposing

## Scientific publications by IMI

- **European Psychiatry, Vol. 50, pp. 57-59**

Vaudano, E. (2018) [Public-private partnerships as enablers of progress in the fight against mental disorders: The example of the European Innovative Medicines Initiative](#)

- **The Lancet, Vol. 388, p. 865**

Matthiessen, L. et al. (2016) [Increased momentum in antimicrobial resistance research](#)

- **Nature Biotechnology, Vol. 33, pp. 811–812 (2015), published online 7 August 2015**

Gunn, M., Lim, M., Cross, D. & Goldman, M. (2015) [Benchmarking the scientific output of the Innovative Medicines Initiative](#)

- **Nature Reviews Drug Discovery, published online 12 December 2014**

Goldman, M., Seigneuret, N. & Eichler, H.-G. (2014) [The Innovative Medicines Initiative: an engine for regulatory science](#)

- **Journal of Health Policy and Outcomes Research, Vol. 2, pp. 12-17**

Wittelsberger, A. & Goldman, M. (2014) [Public-private collaboration to advance the development and benefit-risk assessment of vaccines: The Innovative Medicines Initiative](#)

- **New England Journal of Medicine, Vol. 370, pp. 2163-2165**

Kush, R. & Goldman, M. (2014) [Fostering responsible data sharing through standards](#)

- **Nature Reviews Drug Discovery, Vol.13, pp. 239–240**

Marti-Solano, M., Birney, E., Bril, A., Della Pasqua, O., Kitano, H., Mons, B., Xenarios, I. & Sanz, F. (2014) [Integrative knowledge management to enhance pharmaceutical R&D](#)

itd...



# Future topics



To give potential applicants as much time as possible to form consortia and prepare their proposals, IMI regularly publishes information on possible future topics well in advance of the official Call launch. To ensure you get the latest information on forthcoming Calls, sign up to our [newsletter](#), follow us on [Twitter](#), or join our [LinkedIn group](#).

## IMI2 – Call 17: updated draft texts

The following topics are under consideration for inclusion in the next IMI Call for proposals. These topics are now at an advanced stage of development and we hope that these drafts will allow potential applicants to start working actively on proposals and forming consortia. These topics must be approved by the IMI Governing Board. The final topic text may differ from the draft versions published here, and applicants should always base their proposals on the final, approved topic texts which will be published when the Call is officially launched.

- [Optimising future obesity treatment](#)
- [Open access chemogenomics library and chemical probes for the druggable genome](#)
- [Intelligent prediction and identification of environmental risks posed by human medicinal products](#)

Draft texts updated 29 November 2018

All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.

- [Optimising future obesity treatment](#)
- [Open access chemogenomics library and chemical probes for the druggable genome](#)
- [Intelligent prediction and identification of environmental risks posed by human medicinal products](#)

Teme IMI projekata kreiraju se, između ostalog, u skladu sa prioritetima SZO.

*(European Commission C(2018) 5200 of 6 September 2018)*

# ERC Work Programme 2019



**European Research Council**

Established by the European Commission

## Bottom-up projekti

17% ukupnog  
davanja na  
nauku EU

# Tri faze karijere

	Starting Grant	Consolidator Grant	Advanced Grant and Synergy Grant
Specific Eligibility Criteria	<p>Principal Investigator shall have been awarded his or her first PhD</p> <p>&gt; 2 and ≤ 7 years</p> <p>prior to 1 January 2019</p> <p>Cut-off dates: PhD awarded from 1 January 2012 to 31 December 2016 (inclusive)</p>	<p>Principal Investigator shall have been awarded his or her first PhD</p> <p>&gt; 7 and ≤ 12 years</p> <p>prior to 1 January 2019</p> <p>Cut-off dates: PhD awarded from 1 January 2007 to 31 December 2011 (inclusive)</p>	none

# STARTER

## Early achievements track record

*In the Track record (see "Proposal description" below) the applicant Principal Investigator should list (if applicable):*

- 1. Up to five publications in major international peer-reviewed multi-disciplinary scientific journals and/or in the leading international peer-reviewed journals, peer-reviewed conferences proceedings and/or monographs of their respective research fields, highlighting those as main author or without the presence as co-author of their PhD supervisor (properly referenced, field relevant bibliometric indicators may also be included); preprints may be included, if freely available from a preprint server (preprints should be properly referenced and either a link to the preprint or a DOI should be provided).*
- 2. Research monographs and any translations thereof;*
- 3. Granted patent(s);*
- 4. Invited presentations to internationally established conferences and/or international advanced schools;*
- 5. Prizes, awards, academy memberships.*

**Jedan vrhunski rad** iz oblasti gde je aplikant prvi autor, a PhD supervizor nije deo rada

**Pet solidnih radova** poželjno prvi ili senior autor na većini

**Pozvani predavač** na internacionalnoj konferenciji bar jedanput  
*Poželjno više puta*

**Patenti i nagrade su prednost**

# CONSOLIDATOR

## Early achievements track record

*In the Track Record (see "Proposal description" below) the applicant Principal Investigator should list (if applicable):*

- 1. Up to ten publications in major international peer-reviewed multi-disciplinary scientific journals and/or in the leading international peer-reviewed journals, peer-reviewed conferences proceedings and/or monographs of their respective research fields, highlighting those as main author or without the presence as co-author of their PhD supervisor (properly referenced, field relevant bibliometric indicators may also be included); preprints may be included, if freely available from a preprint server (preprints should be properly referenced and either a link to the preprint or a DOI should be provided).*
- 2. Research monographs and any translations thereof;*
- 3. Granted patent(s);*
- 4. Invited presentations to internationally established conferences and/or international advanced schools;*
- 5. Prizes, awards, academy memberships*

**Tri vrhunska rada** iz oblasti  
gde je aplikant prvi ili  
senior autor, a PhD  
supervizor nije deo rada

**Jedan vrhunski rad** gde je  
aplikant senior autor

**Deset solidnih radova**  
-poželjno prvi ili senior  
autor na većini

**Često pozvani predavač**  
Poželjno više puta

**Patenti i nagrade su  
prednost**

# ADVANCED

## Ten-year track record

*In the Track Record (see "Proposal description" below) the applicant Principal Investigator should list (if applicable):*

- 1. Up to ten representative publications, from the last ten years, **as main author** (or in those fields where alphabetic order of authorship is the norm, joint author) in **major international peer-reviewed multi-disciplinary scientific journals** and/or in the **leading international peer-reviewed journals and peer-reviewed conference proceedings** of their respective research fields (properly referenced, field relevant bibliometric indicators may also be included); preprints may be included, if freely available from a preprint server (preprints should be properly referenced and either a link to the preprint or a DOI should be provided).*
- 2. **Research monographs and any translations thereof;***
- 3. **Granted patents;***
- 4. **Invited presentations to internationally established conferences and/or international advanced schools;***
- 5. **Research expeditions** that the applicant Principal Investigator has led;*
- 6. Organisation of **international conferences** in the field of the applicant (membership in the steering and/or organising committee);*
- 7. **Prizes, awards, academy memberships;***

*8. **Major contributions to the early careers of excellent researchers;***

*9. **Examples of leadership in industrial innovation or design.***

**Veoma kompetitivan, takođe se gledaju:**

**\*Organizacija internacionalnih konferencija**

**\*Sudbina mladih naučnika koji su prošli superviziju**

**\*Uspešna translacija nauke u praktičnu primenu**

# ADVANCED - Benchmark

Thus, in most fields, Principal Investigators of Advanced Grant proposals will be expected to demonstrate a record of achievements appropriate to the field and at least matching one or more of the following benchmarks:

- 10 publications as main author (or in those fields where alphabetic order of authorship is the norm, joint author) in major international peer-reviewed multidisciplinary scientific journals, and/or in the leading international peer-reviewed journals and peer-reviewed conferences proceedings of their respective field;
- 3 major research monographs. This benchmark is relevant to research fields where publication of monographs is the norm.

Other alternative benchmarks that may be considered (individually or in combination) as indicative of an exceptional record and recognition in the last 10 years:

- 5 granted patents;
- 10 invited presentations in well-established internationally organised conferences and advanced schools;
- 3 research expeditions led by the applicant Principal Investigator;
- 3 well-established international conferences or congresses where the applicant was involved in their

organisation as a member of the steering and/or organising committee;

- International recognition through scientific or artistic prizes/awards or membership in well-regarded Academies or artefact with documented use (for example, architectural or engineering design, methods or tools);
- Major contributions to launching the careers of outstanding researchers;
- Recognised leadership in industrial innovation

# SYNERGY

## Objectives

ERC Synergy Grants are intended to foster research at the intellectual frontiers by enabling a **small group of two to four Principal Investigators**, referred to as a 'Synergy Grant Group', and their teams, to bring together complementary skills, knowledge, and resources in new ways to jointly address ambitious research problems.

The aim is to promote substantial advances at the frontiers of knowledge, to cross-fertilize scientific fields, and to encourage new productive lines of enquiry and new methods and techniques, including unconventional approaches and investigations at the interface between established disciplines. This should enable transformative research not only at the forefront of European science but also to become a benchmark on a global scale.

Applicants Principal Investigators must demonstrate the synergies, complementarities and added value that could lead to **breakthroughs that would not be possible by the individual Principal Investigators working alone.**

## Profile of the ERC Synergy Grant Group

Synergy Grant Groups should enable new types of joint effort to allow for new combinations of skills and disciplines, or the bringing together of researchers from different institutions, sectors, countries or parts of the world.

The Synergy Grant Group must be made up of **a minimum of two and a maximum of four Principal Investigators**. One of the Principal Investigators must be designated as the Corresponding Principal



# 17% cele H2020 inicijative u novcu

	<i>Starting Grant</i>	<i>Consolidator Grant</i>	<i>Advanced Grant</i>	<i>Synergy Grant</i>	<i>Proof of Concept Grant</i>
<i>Budget million EUR (estimated number of grants)</i>	580 (390)	602 (314)	391 (166)	400 (48)	25 (167)
<i>Planned dates to inform applicants (after each step or cut-off date)</i>	22/05/2019 28/08/2019	23/07/2019 18/12/2019	31/01/2020 17/04/2020	12/04/2019 30/08/2019 31/10/2019	02/05/2019 25/07/2019 18/12/2019
<i>Indicative date for signature of grant agreements (by cut-off date for PoC)</i>	05/01/2020	26/04/2020	25/08/2020	09/03/2020	09/09/2019 02/12/2019 26/04/2020

# Evaluacija

---

## Proposal description

A complete proposal shall consist of the following elements, with the following page limits<sup>41</sup>.

***Extended Synopsis: 5 pages***

Fokus na aktuelnost i značaj istraživanja

***Curriculum Vitae: 2 pages for each Principal Investigator***

***Track Record: 2 pages for each Principal Investigator***

Fokus na već dobijene projekte

***Scientific Proposal: 15 pages***

Pun opis projekta sa tehničkim detaljima

***Host Institution Binding Statement of Support***

***Ethics Review Table***

***PhD record and supporting documentation for eligibility checking*** (for Starting and Consolidator Grants only).

# Evaluacija

**At step 1**, the extended synopsis and the Principal Investigator's track record and CV will be assessed (and **not** the full scientific proposal). Proposals will be retained for step 2 based on the outcome of the evaluation at step 1 (see below) and a budgetary cut-off level of up to three times the panel's indicative budget.

**At step 2** the complete version of the retained proposals will be assessed (including the full scientific proposal).

# Evaluacija

## Outcome of evaluation

### For Starting, Consolidator and Advanced Grants

At each evaluation step, each proposal will be evaluated and marked for each of the two main elements of the proposal: the ground-breaking nature, ambition and feasibility of the research project; and the intellectual capacity, creativity and commitment of the Principal Investigator.

At the end of each evaluation step, the proposals will be ranked by the panels on the basis of the panels' overall appreciation of their strengths and weaknesses taking into account the marks they have received.


At the end of **step 1** of the evaluation applicants will be informed that their proposal:

**A.** is of sufficient quality to pass to step 2 of the evaluation;

- B.** is of high quality but not sufficient to pass to step 2 of the evaluation;
- C.** is not of sufficient quality to pass to step 2 of the evaluation.

At the end of **step 2** of the evaluation applicants will be informed that their proposal:

- A.** fully meets the ERC's excellence criterion and is recommended for funding **if sufficient funds are available**;
- B.** meets some but not all elements of the ERC's excellence criterion and will not be funded.



# Rezultati u zadnjih 5 godina

Zemlja	Grantovi	Aplikacije	%
Austria	61	359	0,169916
BiH		6	0
Bulgaria		17	0
Croatia		35	0
Czech Republic	13	124	0,104839
France	222	1246	0,17817
Hungary	10	90	0,111111
Israel	118	492	0,239837
Netherlands	196	1085	0,180645
Poland	9	195	0,046154
Romania	5	133	0,037594
Serbia	1	22	0,045455
Slovenia	1	70	0,014286
United Kingdom	326	2552	0,127743

# Međunarodna saradnja/mobilnost/mreže/ bilateralni sporazumi

## Ерасмус + пројекти

1. Пројекат „Унапређење образовања здравствених професионалаца заснованог на практичном искуству у реланом радном окружењу у Србији“ ("Reinforcement of the Framework for Experiential Education in Healthcare in Serbia" / ReFEEHS) одобрен је за финансирање од стране *Erasmus+ programme KA2 – Cooperation for innovation and the exchange of good practices – Capacity Building in*

**2. Са Фармацеутским факултетом Универзитета медицине и фармације „Карол Давила“ из Букурешта, Румунија**

Потписници споразума су се сагласили да ће пружати узајамну подршку у погледу:

- Едукација (семинара, скупова, научним радионица) и истраживачких пројеката;
- Размене студената на свим нивоима наставе, размене наставника и истраживача;
- Коришћења доступне опреме и простора за научна истраживања
- Размене научних информација и писање заједничких публикација

**3. Са Медицинским универзитетом у Бечу, Аустрија**

Потписници споразума су се сагласили да ће пружати узајамну подршку у погледу:

- Припреме заједничких научних публикација
- Размени студената и истраживача.
- Дискусији резултата и координацији заједничких истраживања

# Erasmus+ program (2014 – 2020):

## Ključne akcije (Key Actions):

- **KA1: mobilnosti studenata i nastavnika na osnovu inter-institucionalnih sporazuma**
- **KA2: COOPERATION FOR INNOVATION AND THE EXCHANGE OF GOOD PRACTICES**
- ✓ Capacity building in higher education: support organisations/institutions and systems in their modernisation and internationalisation process
- ✓ Strategic partnership: initiatives addressing one or more fields of education training and youth and promote innovation
- ✓ Knowledge Alliances: between higher education institutions and enterprises which aim to foster innovation, entrepreneurship, creativity, employability
- ✓ Sector Skills Alliance: the design and delivery of joint vocational training curricula, programmes and teaching and training methodologies
- **KA3: SUPPORT FOR POLICY REFORM**
- **JEAN MONNET ACTIVITIES**
  
- Sve detaljne informacije: Erasmus+ program guide
- Nacionalna Erasmus+ kancelarija: <https://erasmusplus.rs>

# Kay Action 1 (KA 103)

- Erasmus+ program **isključivo odlazeće** (*outgoing*) mobilnosti studenata i nastavnika na univerzitetete iz **programskih** zemalja :
  - sve zemlje Evropske unije
  - Makedonija
  - Island
  - Lihtenštajn
  - Norveška
  - Turska



## Kay Action 1 (KA 107)

Erazmus+ program **dolazeće** (*incoming*) i **odlazeće** (*outgoing*) mobilnosti studenata i nastavnika sa/na univerzitetu iz **partnerskih** zemalja:

- Zemlje iz regiona (koje nisu članice EU)
- Drugi delovi sveta

# Kay Action 1 (KA 103/KA107)

## Procedura podnošenja prijava

1. Predlog mobilnosti prema dostavljenom formularu poslati ESPB koordinatorima na Fakultetu (prof. Snežana Savić, doc. Marina Odalović): rok ) **05/08.01.2019!**

Važno je kontaktirati kolege sa partnerske institucije i dostaviti sledeće podatke:

- opšte i kontakt podatke o instituciji,
- podatke o Erasmus+ administratoru sa partnerske institucije
- kontakt podatke o nastavniku koji je kontakt osoba sa partnerske institucije
- kontakt podatke o nastavniku koji je kontakt osoba sa Fakulteta
- Predlog broja mobilnosti (više detalja biće poznato nakon edukacije ESPB koordinatora 17.012.2018.)

2. Popunjavanje on-line formulara i predaja Univerzitetu (od strane ECTS koordinatora): rok **10.01.2019. u 13.00 h!**
3. Univerzitet predaje objedinjenu prijavu svih dostavljenih predloga za saradnju u oblasti KA 103 mobilnosti 05.02.2019.
4. Potpisivanje Interinstitucionalnih sporazuma za odobrene predloge

# Kay Action 1 (KA 103/KA107) - Kriterijumi za odabir (*Relevance/ Usklađenost sa Strategijom internacionalizacije*)

Poštovani,

Obaveštavamo Vas da je na osnovu Interinstitucionalnog sporazuma potpisanog u okviru Erasmus+ KA 1 programa između Univerziteta u Beogradu i Univerziteta University of Granada (UGR), (Spain), a prema dogovoru sa partnerskom institucijom, otvoren konkurs za prijavu za program mobilnosti **Outgoing teaching staff** na University of Granada (UGR), (Spain).

Datum početka prijave kandidata: **17.12.2018. 12:00**

Rok za prijavu kandidata ističe: **12.02.2019. 12:00**

Rok za dostavljanje rang liste Univerzitetu u Beogradu ističe: **19.02.2019. 12:00**

Više detalja o raspoloživom broju mobilnosti možete naći na stranici ugovora [University of Granada \(UGR\) 2017-2019](#)

Srdačan pozdrav,  
Erasmus+ tim Univerziteta u Beogradu

## CEEPUS (Central European Exchange Programme for University Studies)



### Države članice:

- Austrija
- Albanija
- Bosna i Hercegovina
- Bugarska
- Makedonija
- Mađarska
- Moldavija
- Poljska
- Rumunija
- Slovačka
- Srbija
- Slovenija
- Hrvatska
- Crna Gora
- Češka



**Trajanje mobilnosti** direktno zavisi od vrste i kategorije mobilnosti za koju se aplikant prijavljuje. Generalno, CEEPUS studentima omogućava duže boravke, u trajanju od jednog ili dva semestra, radi sticanja kredita, ali i one kratkoročne, u trajanju do tri meseca, sa ciljem istraživanja i pisanja master ili doktorske teze, kao i tzv. kratkoročne ekskurzije, koje se odnose na boravak na zimskim i letnjim školama (trajanja do 6 dana). Kada je reč o mobilnosti profesora, ona može trajati minimalno pet radnih dana uz obavezu 6 predavačkih ili mentorskih sati po radnoj nedelji, a period boravka predavača često traje i mesec dana.



**Visina stipendije** koju svaka zemlja izdvaja za dolazne stipendiste određuje se na osnovu nivoa njenog ekonomskog standarda.



## Stipendije

- **mrežna mobilnost** (*network mobility*) – odvija se u okviru odobrenih CEEPUS mreža, kao i u okviru CEEPUS *umbrella* mreža (mreže koje ispunjavaju standarde kvaliteta, ali nisu među odobrenim mrežama za određenu akademsku godinu). CEEPUS podržava mobilnost studenata različitih nivoa studija, kao i mobilnost nastavnog osoblja;
- **mobilitet izvan CEEPUS mreža** (tzv. *freemover mobility*) – odnosi se na svaku mobilnost između dve visokoškolske institucije koje su prihvatljive za učešće u CEEPUS-u, pri čemu jedna ili obe ustanove nisu uključene u neku od CEEPUS mreža. Osnovna merna jedinica u CEEPUS III programu jeste tzv. „stipendijski mesec”.



## Razmene

- **student** – za studente koji su završili najmanje 2 semestra na matičnoj instituciji. Stipendije se dodeljuju za najmanje tri meseca.
- **kraće mobilnosti studenata** (*short-term student*) – predviđena za studente koji žele da sprovedu istraživanja za završni rad/disertaciju. Minimalno trajanje ove vrste mobilnosti je jedan mesec.
- **kraće ekskurzije** (*short-term excursion*) – za učesnike kratke grupne mobilnosti (poput letnje škole).
- **Teacher** - nastavno osoblje koje učestvuje u CEEPUS programu.



## Uslovi i rokovi za prijavu

- Rok za prijavu za stipendije za zimski semestar je **15. jun**, dok je rok za prijave za letnji semestar **31. oktobar**.
- Pored ova dva roka, postoji i poseban rok za prijavu mobilnosti van mreža (freemovers) – **30. novembar**.



### **Formalni uslovi za učešće u mrežnoj mobilnosti su:**

- aplikant je student ili zaposleni na instituciji koja je deo mreže u okviru koje bi se realizovala mobilnost;
- student mora da ima završena najmanje dva semestra studija;
- nastavno osoblje ima obavezu predavačkog ili mentorskog rada u zemlji- domaćinu od najmanje šest nastavnih sati za svakih pet radnih dana;
- državljanstvo jedne od zemalja članica CEEPUS-a ili status redovnog studenta u jednoj od zemalja članica CEEPUS-a.
- ako student nije državljanin jedne od zemalja-članica programa, a redovni je student u državi-članici CEEPUS-a, treba da priloži potvrdu o akademskom statusu (Equal Status Document).
- i za zaposlene na CEEPUS partnerskoj instituciji koji nemaju državljanstvo države-članice CEEPUS-a postoje dodatni kriterijumi za prijavu (za više informacija, videti pitanje br. 5, odeljak Applying for a CEEPUS grant).

### **Formalni uslovi za *freemover* mobilnosti su:**

- student mora da ima završena najmanje dva semestra studija;
- student mora da pribavi prihvatno pismo od institucije prijema (Freemover Letter of Acceptance) i dva pisma preporuke od matične ustanove (Freemover Letter of Recommendation);
- nastavno osoblje mora da pribavi prihvatno pismo institucije prijema (Freemover Letter Teacher Documentation)
- nastavno osoblje ima obavezu predavačkog ili mentorskog rada u zemlji-domaćinu od najmanje šest nastavnih sati za svakih pet radnih dana;
- prethodno navedeni uslov državljanstva.





### Uključenje u postojeće mreže

- Ukoliko visokoškolska institucija želi da se uključi u neku od postojećih CEEPUS mreža, potrebno je stupiti u kontakt s koordinatorom mreže i ispitati takvu mogućnost.
- *Letter of Endorsement* (rektor ili prorektor)
- *Letter of Intent* (potpisan od strane ovlašćenog lica za međusobno priznavanje za svaki fakultet u okviru prijave).
- Dostaviti i informacije o studijskom programu na engleskom jeziku, koji sadrži informacije o ESPB bodovima.
- Registraciju na glavnoj stranici programa [ceepus.info](http://ceepus.info). Prijavu zatim odobrava Nacionalna CEEPUS kancelarija. Nakon toga koordinator mreže može dodati predloženu jedinicu u CEEPUS mrežu koju koordinira.



### Prijava nove mreže

- Potrebno pronaći najmanje dve institucije sa srodnim programima koje bi učestvovala kao partneri u datoj mreži. Ukoliko institucija želi da koordinira radom određene mreže, preporučuje se da ima prethodno iskustvo u učešću u programu.
- Mreže koje su aktivne u tekućoj akademskoj godini ne moraju da prilažu nova dokumenta za učešće u narednoj akademskoj godini, osim u slučaju uključivanja novih partnera. S druge strane, mreže koje se prijavljuju nakon jednogodišnjeg ili višegodišnjeg perioda neaktivnosti moraju da prate proceduru prijave kao i nove mreže u pogledu dostavljanja dokumentacije.



### Ocenjivanje od strane Nacionalne komisije

- Stručnjaci ocenjuju mreže na osnovu smernica Centralne i Nacionalne CEEPUS kancelarije, dodeljujući im određeni broj poena.
- Tom prilikom se u obzir uzima i usklađenost programa, način na koji svako od partnera doprinosi kvalitetu programa, inovativnost korišćenih pristupa i sl.
- U toku marta sledi objavljivanje rang-liste mreža, kada Centralna CEEPUS kancelarija odlučuje koliko će mreža biti odobreno u narednoj akademskoj godini.
- Pored odobrenih mreža, određeni broj mreža dobija status mreža na rezervnoj listi (*umbrella networks*) koje ne dobijaju stipendijske mesece ali imaju pravo na korišćenje neiskorišćenih stipendijskih meseci u okviru određene akademske godine. Na samom kraju ovog procesa, Međunarodna komisija raspodeljuje ukupnu nacionalnu kvotu između odobrenih mreža.



**СШ-С-0611-08-1819**

**СШ-С-0611-08-1819**

Novel diagnostic and therapeutic approaches to complex genetic disorders

**Participating Units:**



**Contact:**

Dr. Tamas Koszegi  
[tamas.koszegi@aok.pte.hu](mailto:tamas.koszegi@aok.pte.hu)

**Partner**

**University of Belgrade**

**University:** University of Belgrade  
Street: Studentski trg 1  
ZIP / City: 11000 Belgrade  
Country: Serbia  
Phone: +381 11 3027 405, +381 11 3207 153  
Homepage: [www.bn.ac.rs](http://www.bn.ac.rs)

**Institution:** Faculty of Pharmacy, Medical Biochemistry Department  
Street: Vojvode Stepe 450  
ZIP / City: 11000 Belgrade  
Country: Serbia  
Phone: ,  
Homepage: [www.nharmacv.bn.ac.rs](http://www.nharmacv.bn.ac.rs)

- СЕРУС Ш (Central European Exchange Program for University Studies) пројектн

ЦЕЕПУС мрежа „СЕКА PharmTech: Central European Knowledge Alliance for Teaching, Learning & Research in Pharmaceutical Technology“ (СШ-РС-1113-00-1718) – координатор проф. др Јелена Паројчић

СШ-С-0611-08-1819  
Country: Slovenia  
Phone: , 00-386-1-2418-500  
Homepage: [www.uni-lj.si](http://www.uni-lj.si)

**Contact:**

Prof. Janja Marc  
[janja.marc@ffa.uni-lj.si](mailto:janja.marc@ffa.uni-lj.si)

СШ-С-0611-08-1819  
Country: Slovenia  
Phone: ,  
Homepage:

**Program description:**

[Download Long Program Description](#)



Bulgaria



Macedonia



Romania



Kosovo\*

country